Construction and mechanism of histone deacetylation related gene prognosis model in esophageal carcinoma
- 1Department of Thoracic Surgery, Zhejiang Cancer Hospital
Abstract
Histone deacetylases (HDACs) correlate closely with tumor prognosis and serve as therapeutic targets for malignancies. This study aimed to explore esophageal carcinoma (ESCA) therapeutic strategies via identifying histone deacetylation-related prognostic genes. We analyzed The Cancer Genome Atlas (TCGA)-ESCA and GSE53622 datasets, along with 17 histone deacetylation-related genes (HDRGs). Differentially expressed genes (DEGs1) between tumor and normal TCGA-ESCA samples were identified; DEGs2 linked to HDRGs were screened via unsupervised clustering of TCGA-ESCA tumors. Candidate genes were defined as the intersection of DEGs1 and DEGs2, followed by functional enrichment analysis and regression analyses. TCGA-ESCA samples were stratified into high-/low-risk groups, with model validation. Independent prognostic analysis, gene set enrichment analysis (GSEA), immune/gene mutation/drug sensitivity analyses, regulatory network construction, and RT-qPCR validation were performed. The intersection of 3556 DEGs1 and 1622 DEGs2 generated 694 candidates, yielding 7 prognostic genes (UNC13C, MAP7D2, SCARA5 downregulated; SLC35D3, HSPA6, IL31RA, CXCL8 upregulated in tumors). Risk score and pathologic M were independent prognostic factors for nomogram construction, with favorable predictive value. GSEA showed enrichment in pathways like ECM receptor interaction and oxidative phosphorylation; immune correlation, drug sensitivity (e.g., WH.4.023), and RT-qPCR validation of gene expression were confirmed. This study established and verified a novel HDRG-related ESCA prognostic model. The model may serve as a potential tool for risk stratification in ESCA patients and offer new perspectives for exploring the role of histone deacetylation modifications in ESCA progression. However, its clinical translational value, including guiding immunotherapy or targeted drug selection, requires further validation in large-scale prospective studies.
Related
- Multiomics analysis reveals the enhancer landscapes and 3D chromatin architecture in esophageal squamous cell carcinoma
- Histone Lactylation Drives WNK1 Expression to Promote Esophageal Squamous Cell Carcinoma Progression Through Histone H3 Ser10 Phosphorylation
- L013 promotes NRF2 degradation in NRFA-subtype esophageal squamous cell carcinoma
- Multiple sources, shared readouts: the attribution gap in circular RNA immunotherapy for esophageal squamous cell carcinoma
- FAM50A promotes esophageal squamous cell carcinoma progression via splicing-dependent oncogenic circSDK1- and DUSP22-mediated MAPK/FAK activation.
BibTeX
@article{gu2026construction,
title = {{Construction and mechanism of histone deacetylation related gene prognosis model in esophageal carcinoma}},
author = {Yao Gu and Tianxing Ying and Kaiyi Tao and Qiqi Yang and Jian Zeng},
journal = {Scientific Reports},
year = {2026},
month = jul,
doi = {10.1038/s41598-026-62870-z},
url = {https://doi.org/10.1038/s41598-026-62870-z},
note = {CC BY},
}
RIS
TY - JOUR
TI - Construction and mechanism of histone deacetylation related gene prognosis model in esophageal carcinoma
AU - Yao Gu
AU - Tianxing Ying
AU - Kaiyi Tao
AU - Qiqi Yang
AU - Jian Zeng
PY - 2026
DA - 2026/07/01
JO - Scientific Reports
DO - 10.1038/s41598-026-62870-z
UR - https://doi.org/10.1038/s41598-026-62870-z
AB - Histone deacetylases (HDACs) correlate closely with tumor prognosis and serve as therapeutic targets for malignancies. This study aimed to explore esophageal carcinoma (ESCA) therapeutic strategies via identifying histone deacetylation-related prognostic genes. We analyzed The Cancer Genome Atlas (TCGA)-ESCA and GSE53622 datasets, along with 17 histone deacetylation-related genes (HDRGs). Differentially expressed genes (DEGs1) between tumor and normal TCGA-ESCA samples were identified; DEGs2 linked to HDRGs were screened via unsupervised clustering of TCGA-ESCA tumors. Candidate genes were defined as the intersection of DEGs1 and DEGs2, followed by functional enrichment analysis and regression analyses. TCGA-ESCA samples were stratified into high-/low-risk groups, with model validation. Independent prognostic analysis, gene set enrichment analysis (GSEA), immune/gene mutation/drug sensitivity analyses, regulatory network construction, and RT-qPCR validation were performed. The intersection of 3556 DEGs1 and 1622 DEGs2 generated 694 candidates, yielding 7 prognostic genes (UNC13C, MAP7D2, SCARA5 downregulated; SLC35D3, HSPA6, IL31RA, CXCL8 upregulated in tumors). Risk score and pathologic M were independent prognostic factors for nomogram construction, with favorable predictive value. GSEA showed enrichment in pathways like ECM receptor interaction and oxidative phosphorylation; immune correlation, drug sensitivity (e.g., WH.4.023), and RT-qPCR validation of gene expression were confirmed. This study established and verified a novel HDRG-related ESCA prognostic model. The model may serve as a potential tool for risk stratification in ESCA patients and offer new perspectives for exploring the role of histone deacetylation modifications in ESCA progression. However, its clinical translational value, including guiding immunotherapy or targeted drug selection, requires further validation in large-scale prospective studies.
SN - 2045-2322
ER -